Company intelligence / Profile preview
Xaira Therapeutics
Brisbane, California, USAxaira.com ↗
- Ownership
- Private
- Employees
- ~86
- Development stage
- Preclinical
01
Overview
Xaira Therapeutics launched in April 2024 with over $1 billion in committed capital to pioneer the use of artificial intelligence across all stages of drug discovery and development. The company leverages advanced generative AI models—originating from the Institute for Protein Design—to create novel small molecules, proteins, and antibodies targeting challenging disease biology. While specific clinical results are not yet available due to the company's early stage, several preclinical candidates are reportedly advancing toward first-in-human studies.
- Therapeutic areas
- OncologyOther
- Modalities
- Small moleculesProtein therapeutics (including de novo designed proteins and antibodies)Potentially other biologics (company describes "multiple modalities")
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Xaira Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xaira Therapeutics.